Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Satellos Bioscience is a private regenerative medicine company developing novel therapeutics that stimulate or restore muscle regeneration.
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
ConnectRN is a tech-enabled network built to improve clinicians' lives through access to community, opportunity, and support.
Context Therapeutics is a clinical-stage biopharmaceutical company.
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes.
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.
Calyxo is a medical device company that improves kidney stone treatment through specialized urology technologies.
Hyperfine makes MRI accessible to every patient regardless of income or resources.
OrganOx is a medical technology company.
Sirona Medical transforms radiology with a cloud-native platform unifying worklist, viewer, reporter, archive, and AI into one workspace.
858 Therapeutics develops small molecule drugs targeting oncology and immunology.
Helaina is a biotechnology company that focuses on advanced nutrition through the replication of functional proteins.
MBrace Therapeutics is a privately held biopharmaceutical business.
Upstream Health provides technologies and new service approaches for health and social care teams.
UpStream Care is the ideal marketplace solution for medicine.
Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations.
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.
TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.
Innovaccer provides an AI cloud platform for healthcare data management and analytics.
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Field Trip Health is providing simple, evidence-based therapies for healing and heightening engagement with the world.
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Avidity Partners has invested in 32 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Avidity Partners's top investment sectors include Health Care, Biotechnology, Medical, Pharmaceutical, Medical Device. The firm invests across 23 different industry categories.
Among tracked funding rounds, Innovaccer received $275.0M in a Series F round. Avidity Partners's total known invested capital is $2.9B.
Avidity Partners's average investment size is $75.2M across its portfolio of 32 companies.
Recent Avidity Partners portfolio additions include Satellos Bioscience, GentiBio, connectRN, Context Therapeutics, Quanta Therapeutics. These companies were founded in 2020 or later.